Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials.

ABSTRACT:

Background

Mild cognitive impairment (MCI) refers to a transitional zone between normal ageing and dementia. Despite the uncertainty regarding the definition of MCI as a clinical entity, clinical trials have been conducted in the attempt to study the role of cholinesterase inhibitors (ChEIs) currently approved for symptomatic treatment of mild to moderate Alzheimer disease (AD), in preventing progression from MCI to AD. The objective of this review is to assess the effects of ChEIs (donepezil, rivastigmine, and galantamine) in delaying the conversion from MCI to Alzheimer disease or dementia.

Methods and findings

The terms "donepezil", "rivastigmine", "galantamine", and "mild cognitive impairment" and their variants, synonyms, and acronyms were used as search terms in four e

SUBMITTER: Raschetti R 

PROVIDER: S-EPMC2082649 | biostudies-literature | 2007 Nov

REPOSITORIES: biostudies-literature